FCMR抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human lymphoma tissue, Primary antibody: P01349(FCMR Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P01349(FCMR Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of FCMR Antibody**

The Fc mu receptor (FCMR), also known as TOSO or FAIM3. is a transmembrane protein primarily expressed on B lymphocytes and a subset of T cells. It binds to the Fc region of immunoglobulin M (IgM), playing a critical role in regulating B-cell survival, immune complex clearance, and maintaining peripheral tolerance. FCMR is implicated in modulating B-cell receptor (BCR) signaling, where it can either enhance or inhibit apoptosis depending on cellular context, thus influencing immune responses and autoimmune disease progression.

Research highlights FCMR's dual functionality: it promotes B-cell activation and antibody production under certain conditions, while also suppressing excessive immune activation to prevent autoimmunity. Dysregulation of FCMR has been linked to autoimmune disorders (e.g., systemic lupus erythematosus), chronic lymphocytic leukemia (CLL), and infections. FCMR-targeting antibodies are valuable tools for studying its ligand interactions, signaling pathways, and therapeutic potential. Recent studies explore blocking FCMR to counteract pathogenic IgM-mediated inflammation or leveraging it to enhance B-cell targeting in malignancies. However, its complex biology necessitates further research to clarify mechanistic nuances and optimize therapeutic applications.